Revance Therapeutics Inc (RVNC)
3.73
-0.11
(-2.86%)
USD |
NASDAQ |
Nov 22, 16:00
3.725
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Cash from Operations (Quarterly): -41.09M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -41.09M |
| June 30, 2024 | -41.13M |
| March 31, 2024 | -65.94M |
| December 31, 2023 | -42.73M |
| September 30, 2023 | -50.96M |
| June 30, 2023 | -53.38M |
| March 31, 2023 | -69.50M |
| December 31, 2022 | -30.18M |
| September 30, 2022 | -57.87M |
| June 30, 2022 | -44.22M |
| March 31, 2022 | -61.27M |
| December 31, 2021 | -44.61M |
| September 30, 2021 | -53.17M |
| June 30, 2021 | -49.00M |
| March 31, 2021 | -74.76M |
| December 31, 2020 | -62.31M |
| September 30, 2020 | -55.69M |
| June 30, 2020 | -17.21M |
| March 31, 2020 | -43.29M |
| December 31, 2019 | -33.51M |
| September 30, 2019 | -31.95M |
| June 30, 2019 | -29.29M |
| March 31, 2019 | -11.41M |
| December 31, 2018 | -31.14M |
| Date | Value |
|---|---|
| September 30, 2018 | -25.40M |
| June 30, 2018 | -36.56M |
| March 31, 2018 | -11.14M |
| December 31, 2017 | -28.40M |
| September 30, 2017 | -21.46M |
| June 30, 2017 | -24.29M |
| March 31, 2017 | -21.19M |
| December 31, 2016 | -13.47M |
| September 30, 2016 | -14.35M |
| June 30, 2016 | -16.33M |
| March 31, 2016 | -15.68M |
| December 31, 2015 | -16.45M |
| September 30, 2015 | -13.71M |
| June 30, 2015 | -12.49M |
| March 31, 2015 | -13.03M |
| December 31, 2014 | -9.122M |
| September 30, 2014 | -12.69M |
| June 30, 2014 | -12.15M |
| March 31, 2014 | -21.11M |
| December 31, 2013 | -13.98M |
| September 30, 2013 | -6.473M |
| June 30, 2013 | -20.72M |
| March 31, 2013 | -6.583M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-74.76M
Minimum
Mar 2021
-17.21M
Maximum
Jun 2020
-49.59M
Average
-49.98M
Median
Cash from Operations (Quarterly) Benchmarks
| Recursion Pharmaceuticals Inc | -59.22M |
| Regeneron Pharmaceuticals Inc | 1.291B |
| MEI Pharma Inc | -11.45M |
| GlycoMimetics Inc | -7.994M |
| Anebulo Pharmaceuticals Inc | -1.69M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 23.29M |
| Cash from Financing (Quarterly) | -6.087M |
| Free Cash Flow | -194.91M |
| Free Cash Flow Per Share (Quarterly) | -0.3949 |
| Free Cash Flow to Equity (Quarterly) | -41.76M |
| Free Cash Flow to Firm (Quarterly) | -36.88M |
| Free Cash Flow Yield | -54.02% |